학술논문
Mortality and risk factors of vaccinated and unvaccinated frail patients with COVID-19 treated with anti-SARS-CoV-2 monoclonal antibodies: A real-world study
Document Type
article
Author
Riccardo Nevola; Giovanni Feola; Rachele Ruocco; Antonio Russo; Angela Villani; Raffaele Fusco; Stefania De Pascalis; Micol Del Core; Giovanna Cirigliano; Mariantonietta Pisaturo; Giuseppe Loffredo; Luca Rinaldi; Aldo Marrone; Mario Starace; Pellegrino De Lucia Sposito; Domenico Cozzolino; Teresa Salvatore; Miriam Lettieri; Raffaele Marfella; Ferdinando Carlo Sasso; Nicola Coppola; Luigi Elio Adinolfi
Source
International Journal of Infectious Diseases, Vol 131, Iss , Pp 155-161 (2023)
Subject
Language
English
ISSN
1201-9712
Abstract
Objectives: There is a scarcity of data on the outcomes and predictors of therapeutic failure of monoclonal antibodies (mAbs) in frail patients with COVID-19. Methods: Prospective study including consecutive COVID-19 outpatients referred by primary care physicians for mAb treatment. The outcomes evaluated were 60-day mortality, time to SARS-CoV-2 clearance, need for hospitalization, and O2 therapy. Results: Among 1026 COVID-19 patients enrolled, 60.2% received casirivamab/imdevimab and 39.8% sotrivimab. Median age was 63 years, 52.4% were males and median time from positive nasopharyngeal swab to mAbs administration was 3 days (interquartile range, 2-5). 78.1% were vaccinated. Overall, the 60-day mortality was 2.14%. No differences in outcomes were observed between the two mAbs used. No difference was observed in mortality between vaccinated and unvaccinated patients (P = 0.925); although, lower rate of hospitalization (P